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Abstract  
 
Purpose: To evaluate patient-reported outcome measures with the use of ready-made 
spectacles (RMS) and custom spectacles (CS) in an adult population in India with uncorrected 
refractive error (URE). 
 
Design: Prospective double-masked randomized trial with one month follow-up. 
 
Participants: 363 adults aged 18–45 years with ≥1 diopter (D) of URE (RMS, n = 183; CS, n = 
180). 
 
Intervention: All participants received complete refraction, and were randomized to receive CS 
(full sphero-cylindrical correction) or RMS based on the spherical equivalent for the eye with 
lower refractive error but limited to the powers in the RMS inventory.  
 
Main Outcome Measures: Visual Function and Quality of Life instrument (VFQoL), participant 
satisfaction. 
 
Results:  Rasch scores for VFQoL increased from 1.14 to 4.37 logits in the RMS group, and 
from 1.11 to 4.72 logits in the CS group (Respective mean change 3.23 (95% Confidence 
Interval (CI): 2.90-3.56) vs. 3.61(95% CI: 3.34-3.88)).  Mean patient satisfaction also increased 
by 1.83 (95% CI: 1.60-2.06) points on a 5-point Likert scale in the RMS group and 2.04 (95% CI: 
1.83-2.24) points in the CS group.  In bivariate analyses, CS was not associated increased 
VFQoL or patient satisfaction compared to RMS group.  In the full multivariable linear 
regression, the CS group had greater improvement when compared to these receiving RMS 
(+0.45 logits; 95% CI: 0.02 – 0.88), and subjects with astigmatism > 2.00D had significantly less 
improvement (-0.99 logits; 95% CI: -1.68 - -0.30) after controlling for demographic and vision-
related characteristics.   In multivariable analysis, increased change in patient satisfaction was 
related to demographic and optical characteristics, but not spectacle group. 
 
Conclusions:  Ready-made spectacles produce large, but slightly smaller improvements in 
visual function and quality of life, and similar satisfaction with vision at one-month follow-up 
when compared to custom spectacles.  RMS are suitable for the majority of individuals with 
URE in our study population, though those with high degrees of astigmatism may benefit from a 
trial of CS.  This study provides further evidence for use of ready-made spectacles in settings 
where custom spectacles are unavailable, unaffordable, or refractive services are inaccessible 
to those in need.   
 
 
Regulatory and funding agencies are increasingly calling for the use of patient-reported 
outcome measures in all fields of healthcare.1-3  Within ophthalmology, many instruments are in 
use for measuring disability and quality of life related to cataracts,4 diabetic retinopathy,5 age-
related macular degeneration,6 glaucoma,7 and refractive error.8   
 
Uncorrected refractive error (URE) is a major cause of visual impairment and blindness 
worldwide. It is estimated that between 98-153 million people have distance vision worse than 
20/60 due to URE.9, 10  Such impairments are associated with decreased quality of life and 
visual function.11-13  Accordingly, the WHO has made refractive error correction a priority in their 
global campaign to eliminate global blindness: Vision 2020 – The Right to Sight.14, 15  The 
burden of URE is disproportionately borne by persons living in developing countries,15, 16 with 
nearly a quarter of those with distance visual impairment living in India.9  The global economic 
burden of URE has been estimated at $269 billion dollars in productivity losses, and provision of 
care for affected individuals.17, 18 
 
Although the treatment of refractive error with spectacles is technically straightforward, poor 
access to refractive services and high costs limit universal correction in the developing world.19-
21
  Academic, private and humanitarian groups are engaged in spectacle provision for both 
ametropia and presbyopia in developing countries, some of whom have utilized ready-made 
spectacles (RMS).22-25  The cost of refractive error correction is partially driven by the fact that 
custom spectacles (CS) need to be made to order with unique spherical and cylindrical power 
for each eye, and frequently cannot be dispensed at the time of prescribing.  RMS can be 
factory made in bulk using the same spherical power in both eyes, in limited diopter steps, 
frame sizes and styles.  RMS can be dispensed immediately as long as the appropriate 
inventory is maintained.  Theoretically the majority of a population should have acceptable 
vision with RMS.26-28 We have recently reported visual acuity and patient-reported planned 
continued use of RMS compared with CS in children in China25, 29 and adults in India,24 and 
found a comparable degree of acceptability.  
  
In order to determine if RMS are acceptable to a population, validated patient-reported outcome 
measures play a critical role. We recently reported the validation of a novel visual function and 
quality of life instrument using Rasch analysis in an urban Indian population.30  In the present 
study, we use this instrument to compare RMS versus CS in a randomized, prospective, double-
masked trial in Delhi, India.  
 
Subjects and Methods 
The study design has been described in detail elsewhere.24  Briefly, the performance of RMS 
was compared with CS using a prospective, short term (1-month) double-masked randomized 
clinical trial. The Johns Hopkins Medicine Institutional Review Board and the Dr Shroff’s Charity 
Eye Hospital (SCEH) Human Research Ethics Committee approved the study protocol and this 
clinical trial was registered with the US National Institutes of Health Protocol Registration 
System (http://clinicaltrials.gov NCT00657670; last accessed 3/2/2012).  The research adhered 
to the tenets of the Declaration of Helsinki. 
 
Between May and September 2008, 400 adults presenting for care at the SCEH clinic and 
outreach screening camps in Delhi, India were recruited for participation in this study. All 
participants were refracted prior to study enrollment using a standardized protocol24 and 
randomized to receive either the CS prescription based on the full sphero-cylindrical correction 
or RMS prescription based on the spherical equivalent (SE) for the eye with lower refractive 
error but limited to the 25 powers in the RMS inventory. Eligible participants were 18-45 years of 
age, had habitual vision of 20/40 or worse in the better-seeing eye, at least 1 diopter (D) of 
spherical refractive error and were willing to return for follow-up study visits. Study follow-up was 
conducted at one-month.  Study enrollment and follow-up are summarized in Figure 1.  Of the 
initial 400 participants, 10 were excluded due to presenting vision > 20/40 and 27 were lost to 
follow-up; this analysis is limited to the 363 eligible participants (RMS, n = 183; CS, n = 180) 
with baseline and follow-up measures.  We used an intent-to-treat approach.  There were nine 
errors in spectacle orders whereby 7 participants allocated to RMS received their full correction 
and 2 allocated to CS received bilateral spheres.  Data analyses were repeated for treatment 
received. We did not impute outcome measures to address missing follow-up data.  
 
Randomization 
The research optometrists, coordinator and study subjects were masked to the allocation of 
spectacles and remained masked during all visits. After completion of the randomization visit, 
both the CS and RMS prescriptions, pupillary distance, frame choice and participant 
identification number were sent to the dispensing optical shop. The optical technician then 
referred to a computer-generated randomization grid (www.randomization.com accessed April 
1, 2008) with 400 entries and ordered the spectacles according to the group allocation for the 
specific participant identification number. There was no opportunity for the optical shop 
technician to change a subject’s identification number or move the participant to a different 
location on the randomization table. The spectacles were verified as ordered by a technician at 
the optical shop prior to being dispensed. Masking was maintained during all follow-up 
assessments because the spectacles were manufactured at an optical facility separate from the 
testing site, and the RMS and CS were identical in gross appearance. Additionally, those 
involved in data collection were not equipped to measure refractive power of the spectacles 
during assessment and thereby remained masked to the treatment allocation during all 
evaluations. 
 
Outcome measures 
Primary outcome measures for this analysis were patient responses to a Visual Function and 
Quality of Life Instrument validated in this population30 and participant satisfaction.  The 16-item 
Visual Function and Quality of Life Instrument was developed from the 20-item Garamendi-
modified Refractive Status and Vision Profile31 and the 12-item Fletcher Quality of Life scale32 
was piloted, modified, and validated using Rasch analysis.  Logit scores from Rasch analysis of 
the 16-item questionnaire provided an interval measure of participant ability, including mobility, 
social interaction, and visual symptoms at baseline and follow-up.30  Patient satisfaction was 
assessed on a five-point Likert scale using the question “During the past four weeks, how 
satisfied have you been with your vision?” where 0 = Very dissatisfied, 1 = Dissatisfied, 2 = 
Neither satisfied nor dissatisfied, 3 = Satisfied, and 4 = Very satisfied.  A secondary outcome in 
this analysis was distance visual acuity. Visual acuity was measured using tumbling E-charts 
(Precision Vision, Villa Park, IL, USA) with retro-illumination. Visual acuity was scored with 0.02 
logMAR (logarithm of Minimum Angle of Resolution) assigned to each letter.  All measures were 
assessed at baseline and follow-up. 
 
Statistical design and methods 
The primary objective of the analysis was to determine whether receipt of ready-made or 
custom-made spectacles affected patient-reported visual function and quality of life and vision-
related satisfaction.  Responses were scored using Rasch analysis (Andrich model) in WinSteps 
software (ver. 3.67, Chicago, IL) to produce interval scores for each participant based on their 
responses to the 16-item Visual Function and Quality of Life Instrument at baseline and one-
month follow-up. All other analyses were conducted in Stata 11 (College Station, Texas). Chi-
square tests assessed the difference in distributions of Rasch scores between groups at 
baseline and follow-up. To evaluate differences in mean outcome measures between the RMS 
and CS group for baseline, follow-up, and change measures, we used t-tests with a significant 
Type I error rate of 5%.  We had pre-specified secondary analyses of the impact of astigmatism 
and anisometropia on the effect size in the study protocol and thus, sensitivity analyses were 
conducted to determine mean differences in patient-reported outcomes between study groups 
among participants with astigmatism ≥2.00D and anisometropia ≥1.00D.  Multivariable analyses 
were conducted to examine the effect of group on change in Rasch score and patient 
satisfaction, controlling for residual confounding by demographic and vision-related 
characteristics. Interaction terms were introduced to the final multivariable regression models for 
both outcomes to test for the presence of effect modification by astigmatism or anisometropia. 
 
The study was powered to be able to detect a 15% difference in the primary outcome of the 
overall study (rate of continued use of spectacles) at a 5% level of significance with 80% power 
assuming base rate of continued use of 70%. We enrolled 200 subjects into each arm assuming 
a loss to follow-up rate of 10-15% to provide a target 175 in each arm. Our pilot data for the 
patient reported outcomes instrument30 suggested we would be able to measure a difference of 
0.5 logits (power 80%, statistical significance 5%) with this sample size. 
 
Results 
 
The average age in our study population was 30.4 years and nearly 60% were female.   
Participants were generally healthy with few comorbidities.   Approximately 55% of the 
population reported education at the secondary level or below and 79% had annual household 
income less than 60,000 Indian Rupees (RP; approximately United States Dollars (USD)=1500). 
 Though more than half had worn spectacles previously, their presenting vision was on average 
20/70+1 (logMAR = 0.56).  A small proportion had complex refractive error such as 
anisometropia (8%) and 12% had more than 2 diopters of astigmatism (Table 1). The only 
significant difference between the two intervention groups was that the custom spectacle group 
was more likely to have reported seeing an ophthalmologist before.   
 
The distribution of Rasch scores for the Visual Function and Quality of Life instrument are 
presented in Figure 2, panel A and B by study group and time of assessment.  Lower scores 
represent worse function and reduced quality of life.  At baseline, the Rasch scores were 
approximately normally distributed and did not differ between groups (Chi-square p = 0.567).  
The second panel in the figure demonstrates left-skewed Rasch scores representing an 
increase in visual function and quality of life over the one-month follow-up; there was no 
difference in distribution of Rasch follow-up scores between the RMS and CS groups (Chi-
square p = 0.600). 
 
Mean Rasch scores, and patient satisfaction Likert scale scores did not differ between study 
groups as measured at baseline, one-month follow-up or by assessing change in outcome from 
baseline to follow-up.  In the full sample, visual function and quality of life increased by an 
average of 3.23 logits (95% Confidence Interval (CI): 2.90-3.56) in the RMS group and an 
average of 3.61 logits (95% CI: 3.34-3.88) in the CS group.  Mean patient satisfaction also 
increased by 1.83 points (95% CI: 1.60-2.06) on the Likert scale in the RMS group and 2.04 
points (95% CI: 1.83-2.24) in the CS group.  While there was not a statistically significant 
difference at follow-up in mean change for Rasch score and satisfaction between study groups 
in stratified analyses of participants with astigmatism or anisometropia, the magnitude of these 
changes was larger in the CS group. A change of 0.1 logMAR in visual acuity, which represents 
one line on a Snellen chart, was associated with a  2.71 logit increase in Rasch score over the 
study period (p < 0.001) (Figure 3). 
 
Results from bivariate analyses of demographic and vision-related characteristics and change in 
Rasch score are presented as unadjusted regression coefficients in Table 2.  The only 
significant predictor of change in Rasch score in the bivariate analyses was astigmatism greater 
than two diopters in both eyes. In the multivariable linear regression model, the custom 
spectacles group reported marginally significant improvements in visual function and quality of 
life compared to the ready-made spectacles group, equivalent to a 0.45 logit increase in the 
Rasch score (95% CI: 0.02 – 0.88), controlling for age, gender, marital status, education, 
household income, astigmatism greater than two diopters in both eyes, anisometropia greater 
than one diopter, pupil size greater than four millimeters, and presenting vision worse than 
20/63 in the better-seeing eye.  In addition, astigmatism greater than two diopters in both eyes 
at baseline was negatively associated with change in visual function and quality of life, 
controlling for all other variables in the model (-0.99 logits; 95% CI: -1.68 - -0.30).  Tests for 
interaction indicate that there was statistically significantly improved visual function and quality 
of life among those with custom spectacles compared to RMS in those with astigmatism (2.00 
logits; 95% CI: 0.72 – 3.28) and anisometropia (2.13 logits; 95% CI: 0.62 – 3.64) (model not 
shown).  
 
Bivariate and multivariable linear regression models for change in satisfaction were also 
developed. Intervention group was not a significant predictor of change in satisfaction in either 
model.  In bivariate analyses of demographic and vision-related characteristics, education, 
household income, pupil size greater than four millimeters, and astigmatism greater than two 
diopters in both eyes were negatively associated with change in satisfaction. In the full 
multivariable model, income 60,000-120,000 RP compared to income <60,000 RP (-0.50 points; 
95% CI: -0.96 - -0.04), astigmatism greater than two diopters in both eyes (-0.72 points; 95% CI: 
-1.21 -0.23), and pupil size greater than 4 millimeters (-0.33 points; 95% CI: -0.66 -  -0.01) were 
negatively associated with change in satisfaction, controlling for all other variables in the model. 
The addition of an interaction term between study group and astigmatism to the full model 
indicates that there is a statistically significant increase in patient satisfaction among those with 
custom spectacles versus RMS in this subgroup (1.23 points; 95% CI; 0.33 – 2.14) (model not 
shown).  
 
 
Discussion 
This double-masked randomized clinical trial in urban India demonstrates that ready-made 
spectacles (RMS) produce similar changes in patient-reported outcomes of visual function, 
quality of life, and satisfaction with vision at one-month follow-up when compared to custom 
spectacles (CS).  This is despite the fact that those in the RMS group did not have fully 
corrected vision.24  With our previous findings on the equivalent uptake of ready-made 
spectacles and custom spectacles in this population,24 this study supports more widespread use 
of ready-made spectacles in settings where custom spectacles are unavailable or unaffordable 
and refractive services are inaccessible to those in need. 
 
The ability to use RMS as the foundation of outreach or humanitarian efforts to combat 
uncorrected refractive error is attractive for financial and practical reasons. Although the present 
study did not source actual RMS, the cost savings for the spectacles should be significant.22  
Additionally the ability to dispense spectacles at the time of refraction allows for dramatically 
simplified logistics, as long as an appropriate inventory of RMS is maintained.   
 
We previously estimated that approximately 10% of this population would have refractive needs 
that are not met by RMS.24, 25  Additionally, a recent review of global epidemiologic studies 
found rates ranging from 15.8 to 48.9% for astigmatism greater than 0.5 to 1.0 diopters.33  In our 
study population, approximately 12% had astigmatism greater than 2.00 diopters, and this group 
had smaller gains in reported vision function and quality of life at follow-up, controlling for 
demographic and vision-related characteristics. Subgroup analyses show that there clearly are 
some who would be best served with custom spectacles.  While these people are more likely to 
have higher degrees of astigmatism or anisometropia, the findings reported here and our prior 
reports from this dataset did not support the use of refractive cutoffs to exclude people from 
receiving RMS. Since RMS can be tried on immediately and worn in the vision testing setting, 
one could use this approach to identify persons who would not tolerate RMS well. Based on our 
findings, when integrating RMS into refractive service delivery, a mechanism should be in place 
to detect high levels of astigmatism and offer these individuals custom spectacles.  
 
Visual function and quality of life was not associated with higher level of education or income, 
factors which could be associated with higher visual demand.  Higher income and education 
were, however, associated with a reduced degree of improvement in satisfaction, though this 
was independent of treatment group assignment.  It is still possible that individuals with unique 
spectacle needs could be expected to be the most discerning in a population, and so might be 
more likely to return for follow-up visits for dispensation should the decision to prescribe CS be 
made.  
 
The use of a patient-reported outcome as a primary endpoint has pitfalls since it is, by its very 
nature, subjective. By using Rasch analysis to validate our visual function questionnaire,30 we 
have demonstrated that our instrument is valid, mathematically robust, and well-targeted to this 
population.  We showed a clinically important improvement in Rasch score of 3.23 and 3.61 
logits in the RMS and CS groups respectively.  This magnitude of this improvement is in line 
with change in logits after cataract extraction.4  
 
Additionally, results from our subgroup analyses show that there is a larger absolute difference 
between the change in Rasch scores in the CS compared to the RMS group within those 
patients with astigmatism >2.00D or anisometropia >1.00D.  This provides a degree of face 
validity.  Moreover, there was a clear positive linear relationship between improvement in visual 
acuity and improvement in Rasch score, demonstrating that our measure also has criterion 
validity. We had 21 subjects with astigmatism in both the RMS and CS groups and 15 subjects 
with anisometropia in both groups. While the findings of our study suggest improved patient 
satisfaction and vision-related quality of life in the CS group compared to the RMS group among 
the small number of participants with astigmatism or anisometropia, the study was 
underpowered to detect a clinically meaningful difference in these subgroups. Future studies 
with targeted recruitment of participants with astigmatism and anisometropia are needed to 
confirm that CS is preferable to RMS in these subgroups before designing programs without a 
“try-before-you-buy” option. Future research might also seek to address whether individuals with 
higher visual demand, either recreationally or professionally, have a preference for CS in the 
setting of astigmatism or anisometropia. Future research should seek to attain longer follow-up 
as long-term spectacle acceptance may not mirror our 1 month results.34 
 
Important strengths of the study include randomized design, large sample size, low loss to 
follow-up, and use of validated visual function instrument.  
 
In conclusion, this research demonstrates similar large improvements in patient reported visual 
function with the provision of either ready-made or custom spectacles. We believe that the 
acceptability and affordability support the provision of RMS in those settings where CS are 
impractical, or where the cost of which would limit the number of those who could benefit. As 
resources permit, and access to refractive services improve, we expect more people opting to 
pay a premium for custom spectacles, but until that time, we predict high levels of satisfaction 
with ready-made spectacles.  
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 Table 1. Characteristics of study participants at baseline (n = 363).   
 
      
Ready-made 
spectacles   
Custom 
spectacles   
   (n = 183)  (n = 180)  
      n (%)   n (%)   
Demographic characteristics 
      
 Age, mean (SD) 30.36 (9.39)  30.41 (8.93)  
 Male 75 (40.98)  79 (43.89)  
 Married 103 (56.28)  102 (56.67)  
 Education       
  Illiterate 27 (14.75)  23 (12.78)  
  Primary school 43 (23.50)  41 (22.78)  
  Secondary school 36 (19.67)  30 (16.67)  
  Higher secondary school 30 (16.39)  35 (19.44)  
  Graduate, post-graduate, professional school 47 (25.68)  51 (28.33)  
 Annual household income in Indian Rupees (RP)       
  <60,000 RP (< USD $1500) 145 (79.23)  136 (75.56)  
  60,000 - 120,000 RP (USD $1500 - 3000) 20 (10.93)  29 (16.11)  
  >120,000 RP (> USD $3000) 13 (7.10)  12 (6.67)  
         
Health-related characteristics 
      
 General rating of health       
  Excellent 9 (4.82)  11 (6.11)  
  Very good 19 (10.38)  14 (7.78)  
  Fair 39 (21.31)  41 (22.78)  
  Poor 116 (63.39)  114 (63.33)  
 Ever smoke tobacco 14 (7.65)  13 (7.22)  
 Ever drink alcohol 11 (6.01)  6 (3.33)  
 Hypertension, diabetes or heart disease 6 (3.28)  3 (1.67)  
         
Vision-related characteristics 
      
 Ever seen ophthalmologist 99 (54.10)  128 (71.11)  
 Ever worn spectacles 102 (55.74)  104 (58.10)  
 
Uncorrected vision in better eye at baseline, mean 
logMAR (SD) 0.56 (0.21)  0.57 (0.21)  
 
Uncorrected vision in worse eye at baseline, mean 
logMAR (SD) 0.60 (0.21)  0.62 (0.22)  
 Astigmatism ≥2.00D in both eyes 21 (11.48)  21 (11.67)  
 Anisometropia ≥1.00D 15 (8.20)  15 (8.33)  
  
Anisometropia ≥1.00D and  ≥2.00D astigmatism in 
both eyes 35 (19.13)   31 (17.22)   
 
Missing data: age (1 Ready Made Spectacles (RMS), 1 Custom (CS)), income (5 RMS, 3 CS). Bold values indicate p 
< 0.05. SD = standard deviation, RP = Indian Rupees, USD = United States Dollars, logMAR = logarithm of the 
minimum angle of resolution, D = diopters.
Table 2. Linear regression of change in Rasch score and satisfaction 
 
  Change in Rasch score  Change in satisfaction 
  Unadjusted Adjusted  Unadjusted           Adjusted 
    Coeff.   (95% CI) Coeff.   (95% CI)  Coeff.   (95% CI) Coeff.   (95% CI) 
Study group              
 Ready-made spectacles Ref.   Ref.    Ref.   Ref.   
 Custom spectacles 0.38  (-0.05 - 0.80) 0.45  (0.02 - 0.88)  0.21  (-0.10 - 0.51) 0.22  (-0.08 - 0.53) 
Age 0.02  (0.00 - 0.04) 0.01  (-0.02 - 0.05)  0.01  (-0.01 - 0.03) 0.00  (-0.02 - 0.03) 
Gender              
 Female Ref.   Ref.    Ref.   Ref.   
 Male -0.29  (-0.72 - 0.14) -0.22  (-0.68 - 0.23)  -0.21  (-0.52 - 0.10) -0.14  (-0.46 - 0.18) 
Marital status              
 Married Ref.   Ref.    Ref.   Ref.    
 Single -0.37  (-0.80 - 0.06) -0.07  (-0.73 - 0.59)  -0.22  (-0.53 - 0.09) -0.03  (-0.50 - 0.44) 
Education              
 Illiterate Ref.   Ref.    Ref.   Ref.   
 Primary school -0.12  (-0.84 - 0.61) 0.11  (-0.65 - 0.87)  0.01  (-0.51 - 0.53) 0.17  (-0.37 - 0.71) 
 Secondary school -0.35  (-1.11 - 0.41) 0.02  (-0.81 - 0.84)  -0.24  (-0.78 - 0.30) -0.01  (-0.60 - 0.58) 
 Higher secondary school -0.62  (-1.39 - 0.14) -0.29  (-1.15 - 0.57)  -0.29  (-0.83 - 0.26) -0.04  (-0.66 - 0.57) 
 Graduate, post-graduate, professional school -0.32  (-1.03 - 0.38) -0.05  (-0.85 - 0.75)  -0.57  (-1.07 - -0.07) -0.45  (-1.02 - 0.11) 
Annual household income in Indian Rupees (RP)              
 <60,000 RP (< USD $1500) Ref.   Ref.    Ref.   Ref.   
 60,000 - 120,000 RP (USD $1500 - 3000) -0.58  (-1.21 - 0.05) -0.58  (-1.23 - 0.06)  -0.57  (-1.02 - -0.12) -0.50  (-0.96 - -0.04) 
 >120,000 RP (> USD $3000) -0.21  (-1.06 - 0.64) -0.10  (-0.98 - 0.78)  -0.36  (-0.96 - 0.25) -0.10  (-0.73 - 0.52) 
Astigmatism ≥2.00D in both eyes -1.00  (-1.66 - -0.34) -0.99  (-1.68 - -0.30)  -0.68  (-1.15 - -0.21) -0.72  (-1.21 - -0.23) 
Anisometropia ≥1.00D -0.19  (-0.96 - 0.59) -0.23  (-1.03 - 0.57)  0.29  (-0.26 - 0.84) 0.38  (-0.19 - 0.95) 
Pupil size ≥ 4mm -0.42  (-0.86 - 0.03) -0.31  (-0.77 - 0.16)  -0.35  (-0.67 - -0.03) -0.34  (-0.66 - -0.01) 
Presenting vision worse than 20/63 in the better eye 0.30  (-0.13 - 0.72) 0.42  (-0.02 - 0.87)  0.17  (-0.14 - 0.47) 0.25  (-0.06 - 0.57) 
Intercept -     2.75   (0.57 - 4.94)        1.93   (0.38 - 3.48) 
 
CI = 95% Confidence Interval, USD = United States Dollars, D = diopters. 
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Legends 
Figure 1. Flow chart of study participants progress through the clinical trial. RMS = ready-made 
spectacles, CS = custom spectacles. 
 
Figure 2. Rasch scores at baseline and follow-up, by group. RMS = ready-made spectacles. 
 
Figure 3. Change in Rasch scores and visual acuity from baseline to follow-up (n=363). A 
change of 0.1 logMAR in visual acuity (one line Snellen acuity), was associated with a  2.71 logit 
increase in Rasch score over the study period. logMAR = logarithm of the minimal angle of 
resolution. 
 
 
